GoodRx (NASDAQ:GDRX) Price Target Lowered to $5.50 at Truist Financial

GoodRx (NASDAQ:GDRX) had its price target trimmed by Truist Financial from $6.50 to $5.50 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a hold rating on the stock.

Several other equities analysts have also recently commented on GDRX. KeyCorp lowered their price target on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Citigroup lowered their target price on GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research note on Friday, January 10th. Morgan Stanley cut their price target on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Finally, Wells Fargo & Company reduced their price target on GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.93.

GoodRx Stock Performance

GDRX stock opened at $4.32 on Thursday. The firm has a 50 day simple moving average of $4.66 and a 200 day simple moving average of $5.08. GoodRx has a 52 week low of $3.82 and a 52 week high of $9.26. The stock has a market cap of $1.66 billion, a P/E ratio of -144.00, a P/E/G ratio of 2.46 and a beta of 1.25. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48.

Institutional Investors Weigh In On GoodRx

A number of large investors have recently added to or reduced their stakes in the stock. National Bank of Canada FI boosted its stake in GoodRx by 34.9% during the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company’s stock valued at $39,000 after purchasing an additional 2,151 shares during the period. Gotham Asset Management LLC increased its position in GoodRx by 31.0% in the 4th quarter. Gotham Asset Management LLC now owns 17,677 shares of the company’s stock worth $82,000 after buying an additional 4,182 shares during the period. Gagnon Securities LLC lifted its holdings in shares of GoodRx by 9.9% during the fourth quarter. Gagnon Securities LLC now owns 69,867 shares of the company’s stock worth $325,000 after buying an additional 6,266 shares during the last quarter. Swiss National Bank boosted its position in shares of GoodRx by 4.1% in the fourth quarter. Swiss National Bank now owns 161,400 shares of the company’s stock valued at $751,000 after acquiring an additional 6,400 shares during the period. Finally, Fortem Financial Group LLC grew its stake in shares of GoodRx by 7.2% in the fourth quarter. Fortem Financial Group LLC now owns 119,179 shares of the company’s stock worth $554,000 after acquiring an additional 7,996 shares during the last quarter. Institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.